ResMed Sells MatrixCare to Sharpen Its Sleep-Tech Focus—But the Market's Applause Stays Muted

Aditi Sarkar

29 July 2026 10:34 PM AEST

ResMed Sells MatrixCare to Sharpen Its Sleep-Tech Focus—But the Market's Applause Stays Muted

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

On 7 July 2026, ResMed announced a definitive agreement to sell MatrixCare to Frazier Healthcare Partners, a US healthcare-focused private-equity firm, for US$490 million.
ResMed's latest reported figures are for the third quarter of FY2026, the quarter ended 31 March 2026; the full-year and Q4 result is not.
ResMed Inc. (NYSE: RMD; ASX: RMD) has returned to investor conversations after agreeing to sell its MatrixCare out-of-hospital software business, unwinding part of a.
The risks are genuine. Philips is re-entering the US sleep-device market in 2026 after its recall-driven retreat, threatening ResMed's recent share gains. The GLP-1.

ResMed Inc. (NYSE: RMD; ASX: RMD) has returned to investor conversations after agreeing to sell its MatrixCare out-of-hospital software business, unwinding part of a decade-long diversification push to refocus on its core sleep-apnoea and connected-breathing franchise. For Australian investors, ResMed is a familiar name with local roots but a US primary listing; its ASX securities trade as CHESS Depositary Interests (CDIs), and the company reports in US dollars with a 30 June financial year-end. The decision lands while the stock sits well below its highs, caught between resilient earnings and an unresolved debate over whether GLP-1 weight-loss drugs will erode or expand demand for its devices.

The latest development: a signed, not completed, sale

On 7 July 2026, ResMed announced a definitive agreement to sell MatrixCare to Frazier Healthcare Partners, a US healthcare-focused private-equity firm, for US$490 million in cash. The transaction is signed but not yet closed; ResMed expects completion in the first quarter of its 2027 financial year — the three months to 30 September 2026 — subject to regulatory approvals and customary conditions. MatrixCare provides software to more than 15,000 providers across skilled nursing, senior living, long-term care and home health and hospice, and the sale bundles in the HealthcareFirst, Citus and related home-health assets.

About ResMed

ResMed (ASX:RMD) is an Australian-listed company whose current investor narrative centres on the operational, financial and strategic developments discussed above. Its share price may respond to both company-specific execution and broader sector conditions.

What Investors May Watch Next

The evidence supports a measured verdict rather than a bullish call.
ResMed's fundamentals — double-digit revenue growth, 60%-plus gross margins and 21% EPS growth — are robust, and the MatrixCare sale is a credible sharpening of strategy with shareholder-friendly.
But the deal is signed, not done, the market's response was muted, and the GLP-1 and Philips questions are unresolved.
Whether any next leg higher is 'just beginning' depends on the 6 August result and on data, not narrative.

Risks

The risks are genuine. Philips is re-entering the US sleep-device market in 2026 after its recall-driven retreat, threatening ResMed's recent share gains. The GLP-1 debate could resurface if long-term data disappoints. Integration costs — Noctrix is expected to be a modest EPS headwind — and stranded costs from the MatrixCare exit may weigh temporarily. Regulatory approval of the sale is not guaranteed, and currency swings affect both reported results and the A$ value of CDIs.

FAQs

Q: What is the latest update from ResMed?

A:On 7 July 2026, ResMed announced a definitive agreement to sell MatrixCare to Frazier Healthcare Partners, a US healthcare-focused private-equity firm, for US$490 million in cash. The transaction is signed but not yet closed; ResMed expects completion in the first quarter of its 2027 financial year — the three months to 30 September 2026 — subject to regulatory approvals and customary conditions.

Q: What is happening with the RMD share price?

A:ResMed Inc. (NYSE: RMD; ASX: RMD) has returned to investor conversations after agreeing to sell its MatrixCare out-of-hospital software business, unwinding part of a decade-long diversification push to refocus on its core sleep-apnoea and connected-breathing franchise.

Q: What do the latest financial figures show?

A:ResMed's latest reported figures are for the third quarter of FY2026, the quarter ended 31 March 2026; the full-year and Q4 result is not due until 6 August 2026, after this article's research cut-off. The Q3 numbers were strong.

Q: What may investors watch next for ResMed?

A:Investors may watch the next financial result, management guidance, progress on the company’s stated strategy and the share-price response to new information.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.